ETF Holdings Breakdown of BEAM

News associated with BEAM

QRG Capital Management Inc. Sells 870 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)

QRG Capital Management Inc. cut its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 5.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,635 shares of the company’s stock after selling 870 shares during the period. QRG […] - 2025-06-24 07:46:59

Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Recommendation of “Buy” by Analysts

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has been assigned an average recommendation of “Buy” from the fifteen analysts that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the […] - 2025-06-23 07:48:53

Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Northern Trust Corp

Northern Trust Corp boosted its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 7.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 740,506 shares of the company’s stock after acquiring an additional 49,415 shares during the period. Northern Trust […] - 2025-05-14 08:54:50

Stifel Financial Corp Acquires 2,976 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)

Stifel Financial Corp boosted its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 27.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,662 shares of the company’s stock after acquiring an additional 2,976 shares during the quarter. Stifel Financial Corp’s […] - 2025-05-14 07:56:47

Beam Therapeutics (NASDAQ:BEAM) Trading Down 6.8% Following Weak Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) shares traded down 6.8% during mid-day trading on Tuesday following a dissappointing earnings announcement. The company traded as low as $18.37 and last traded at $18.47. 326,775 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 1,947,803 shares. The stock […] - 2025-05-08 05:42:51

Dimensional Fund Advisors LP Has $38.16 Million Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM)

Dimensional Fund Advisors LP boosted its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 24.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,538,398 shares of the company’s stock after purchasing an additional 298,067 shares during the period. Dimensional Fund Advisors […] - 2025-05-05 08:20:53

Beam Therapeutics Inc. (NASDAQ:BEAM) Stake Lifted by Sterling Capital Management LLC

Sterling Capital Management LLC raised its stake in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 816.0% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 2,409 shares of the company’s stock after buying an additional 2,146 shares during the quarter. Sterling Capital Management LLC’s holdings in Beam […] - 2025-04-24 09:31:07

Beam Therapeutics Target of Unusually Large Options Trading (NASDAQ:BEAM)

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Investors acquired 10,060 put options on the company. This is an increase of approximately 1,089% compared to the typical daily volume of 846 put options. Beam Therapeutics Stock Up 3.9 % Beam Therapeutics stock opened at […] - 2025-04-24 05:30:49

Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by LPL Financial LLC

LPL Financial LLC grew its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 5.6% during the fourth quarter, Holdings Channel reports. The firm owned 27,698 shares of the company’s stock after acquiring an additional 1,462 shares during the quarter. LPL Financial LLC’s holdings in Beam Therapeutics were worth $687,000 as of […] - 2025-04-23 07:22:56

Federated Hermes Inc. Decreases Position in Beam Therapeutics Inc. (NASDAQ:BEAM)

Federated Hermes Inc. decreased its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 20.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 29,709 shares of the company’s stock after selling 7,792 shares during the quarter. Federated Hermes Inc.’s holdings in Beam Therapeutics were worth $737,000 as of its most recent SEC filing. […] - 2025-04-17 08:16:55

Beam Therapeutics Inc. (NASDAQ:BEAM) Holdings Decreased by Russell Investments Group Ltd.

Russell Investments Group Ltd. cut its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 6.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 176,181 shares of the company’s stock after selling 11,664 shares during the period. Russell Investments Group Ltd.’s holdings in Beam Therapeutics were worth $4,369,000 as of its […] - 2025-04-16 08:06:53

Geode Capital Management LLC Trims Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)

Geode Capital Management LLC cut its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 0.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,804,374 shares of the company’s stock after selling 3,309 shares during the quarter. Geode Capital Management […] - 2025-04-15 08:01:01

JPMorgan Chase & Co. Sells 125,567 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)

JPMorgan Chase & Co. lowered its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 19.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 513,671 shares of the company’s stock after selling 125,567 shares during the period. […] - 2025-04-14 07:36:51

Alliancebernstein L.P. Has $5.28 Million Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)

Alliancebernstein L.P. lifted its stake in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 149.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 212,804 shares of the company’s stock after purchasing an additional 127,494 shares during the quarter. Alliancebernstein L.P.’s holdings in […] - 2025-04-13 08:44:47

KLP Kapitalforvaltning AS Makes New Investment in Beam Therapeutics Inc. (NASDAQ:BEAM)

KLP Kapitalforvaltning AS purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 13,400 shares of the company’s stock, valued at approximately $332,000. Other hedge funds and other institutional investors have […] - 2025-04-06 10:35:04

Mitsubishi UFJ Asset Management Co. Ltd. Has $244,000 Stake in Beam Therapeutics Inc. (NASDAQ:BEAM)

Mitsubishi UFJ Asset Management Co. Ltd. lowered its position in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 9.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,613 shares of the company’s stock after selling 995 shares during the period. Mitsubishi UFJ Asset Management Co. […] - 2025-04-04 08:12:58

AlphaQuest LLC Reduces Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)

AlphaQuest LLC trimmed its stake in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 92.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,610 shares of the company’s stock after selling 33,583 shares during the period. AlphaQuest LLC’s holdings in Beam Therapeutics […] - 2025-03-20 08:13:05

Beam Therapeutics (NASDAQ:BEAM) Earns Overweight Rating from Cantor Fitzgerald

Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “overweight” rating reaffirmed by research analysts at Cantor Fitzgerald in a research report issued on Wednesday,Benzinga reports. BEAM has been the subject of several other research reports. Guggenheim reaffirmed a “buy” rating and issued a $78.00 price objective on shares of Beam Therapeutics in a […] - 2025-03-14 06:44:57

Analysts Set Beam Therapeutics Inc. (NASDAQ:BEAM) Target Price at $51.00

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has been given an average recommendation of “Buy” by the fourteen research firms that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to […] - 2025-03-13 06:06:47

Beam Therapeutics (NASDAQ:BEAM) Stock Rating Upgraded by Scotiabank

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) was upgraded by equities research analysts at Scotiabank from a “sector perform” rating to a “sector outperform” rating in a report released on Monday, MarketBeat.com reports. The firm presently has a $40.00 target price on the stock. Scotiabank’s price objective would suggest a potential upside of 51.40% from […] - 2025-03-12 06:41:41

Beam Therapeutics (NASDAQ:BEAM) Earns Buy Rating from HC Wainwright

Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $80.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 202.80% from the stock’s previous close. Several […] - 2025-03-12 06:41:35

Beam Therapeutics To Present At Barclays Global Healthcare Conference; Webcast At 3:30 PM ET

(RTTNews) - Beam Therapeutics Inc. (BEAM) will present at the Barclays Global Healthcare Conference. - 2025-03-11 18:29:33

Beam Therapeutics To Present At Leerink Partners Global Biopharma Conference; Webcast At 1:40 PM ET

(RTTNews) - Beam Therapeutics Inc. (BEAM) will present at the Leerink Partners Global Biopharma Conference. - 2025-03-10 16:44:28

Beam Therapeutics (NASDAQ:BEAM) Trading Up 7.9% Following Analyst Upgrade

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) was up 7.9% during trading on Tuesday after Scotiabank raised their price target on the stock from $24.00 to $25.00. Scotiabank currently has a sector perform rating on the stock. Beam Therapeutics traded as high as $26.84 and last traded at $27.09. Approximately 1,184,373 shares traded hands […] - 2025-03-05 08:28:50

Beam Therapeutics (NASDAQ:BEAM) Shares Gap Up on Earnings Beat

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report)’s share price gapped up before the market opened on Tuesday following a stronger than expected earnings report. The stock had previously closed at $30.79, but opened at $32.10. Beam Therapeutics shares last traded at $29.95, with a volume of 195,938 shares trading hands. The company reported ($1.09) […] - 2025-02-27 07:10:47

Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have been given a consensus rating of “Buy” by the twelve brokerages that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and two have issued a strong buy […] - 2025-02-13 08:40:54

Blue Trust Inc. Grows Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)

Blue Trust Inc. increased its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 36.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 4,274 shares of the company’s stock after acquiring an additional 1,139 shares during the period. Blue Trust Inc.’s holdings in Beam Therapeutics were worth $105,000 at the end […] - 2025-02-07 08:32:50

BEAM institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	60,138	USD 1,030,765
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	9,377	USD 160,722
2025-06-26	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	124,478	USD 2,133,553
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	50,182	USD 860,119
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	50,182	USD 860,119
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	483	USD 8,279
Total =		294,840	USD 5,053,557

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer